All News I-Mab

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.75 ^USD	-1.13%		-3.31%	-7.89%

Apr. 18	Verastem Names John Hayslip as Chief Medical Officer	MT
Apr. 15	I-Mab Announces Chief Medical Officer Changes	CI

I-MAB Filed 2023 Annual Report on Form 20-F	Apr. 30	PR
Verastem Names John Hayslip as Chief Medical Officer	Apr. 18	MT
I-Mab Announces Chief Medical Officer Changes	Apr. 15	CI
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 08	AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 05	PR
I-Mab Completes Business Divestiture in China	Apr. 02	MT
I-Mab Announces Closing of the Divestiture of Business Operations in China	Apr. 02	PR
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	Apr. 01	CI
I Mab : Resignations of Director and Senior Management - Form 6-K	Apr. 01	PU
I-Mab Announces Executive Resignation	Apr. 01	CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	Mar. 18	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	Mar. 15	MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
I-Mab Divests China Operations, Shifts Focus to US Market	Feb. 08	MT
ADRs Close Higher, Renalytix PLC Climbs 96.9%	Feb. 08	DJ
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	Feb. 08	AQ
Biotech firm I-Mab to divest China operations, shift focus to US	Feb. 07	RE
Biotech firm I-Mab to divest China operations	Feb. 07	RE
I-Mab Announces Board Changes , Effective February 10, 2024	Feb. 07	CI

No results for this search